Media

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

HealthCap portfolio company Fusion Pharmaceuticals to be acquired by AstraZeneca for up to USD 2.4 billion

Fusion Pharmaceuticals To Be Acquired By AstraZeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer

Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis

BONESUPPORT – CERAMENT® G RECEIVES FDA CLEARANCE FOR OPEN FRACTURES

Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH

Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Oncopeptides carries out a fully guaranteed rights issue of approximately SEK 300 million to reach profitability during 2026

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers